MSH2 and colorectal carcinoma: We next evaluated the efficacy of GSK_WRN4 in a patient-derived xenograft (PDX) model from a patient with treatment-refractory MSI CRC, characterized by frameshift mutations in MSH2, MSH3, MSH6, and a pathogenic TP53 missense mutation.